A Single-Use ADC Process: From Development to Clinical.
Berthold Boedeker, Biotech Development.
Design, Development & Stability of ADCs: How do they differ from mAbs?
Mary E. Krause, Ph.D., Bristol-Myers Squibb
Andreas Pahl, Heidelberg Pharma GmbH, Ladenburg, Germany
Alain Beck, PhD Sr. Director, Antibody Physico-Chemistry Centre d’Immunologie Pierre Fabre, FR Associate Editor, mAbs, US
Cécile Combeau, Early Development Oncology, Sanofi
Gain invaluable insight on the latest news of ADCs progressing in the clinic.
Lead author: Jian Wang, Analytical & Bioanalytical Operations, Bristol-Myers Squibb,